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Abstract
The use of chemotherapeutic agents in the management of cancer is often followed by a range of toxicities 
to various organ systems. A retrospective study on the hematologic toxicities of chemotherapy in lung 
cancer patients has been carried out. The study was conducted by a cross-sectional method from medical 
records of four-year data in 2010–2014 at Dr. M. Djamil Hospital Padang, West Sumatra, Indonesia. 
Data from medical records of patients diagnosed with lung cancer and underwent chemotherapy, 
not suffering from primary hematologic diseases, and with normal kidney and liver function prior to 
chemotherapy were studied. A number of 22 medical records of lung cancer patients which met the 
criteria with a total of 40 chemotherapy cycles were observed. The study revealed that a combination 
of carboplatin-paclitaxel was the most common chemotherapy used for the patients (72.7%). The 
hematologic toxicities comprised anemia, leukopenia, and thrombocytopenia with the severity ranging 
from grade 1–3. Carboplatin-paclitaxel was the only combination that caused these three toxicities, and 
the only combination to cause thrombocytopenia as well. Anemia was the major hematologic toxicity 
experienced by more than half of the patients. The study concludes that there is a reasonably high 
incidence of hematologic toxicities from chemotherapy among lung cancer patients. 
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Toksisitas Hematologis Akibat Kemoterapi pada Pasien Kanker Paru: 
Studi Retrospektif di RSUP Dr. M. Djamil Padang
Abstrak 
Penggunaan obat kemoterapi dalam pengobatan kanker sering disertai dengan toksisitas pada beberapa 
sistem organ. Kajian retrospektif terhadap toksisitas hematologis akibat kemoterapi pada pasien kanker 
paru sudah dilaksanakan. Studi ini dilaksanakan dengan metode cross-sectional dari data rekam 
tahun 2010–2014 di RSUP Dr. M. Djamil Padang, Sumatera Barat. Data pasien yang didiagnosis 
menderita kanker paru yang menjalani kemoterapi, tidak menderita penyakit hematologis dan gangguan 
hematopoiesis, serta memiliki fungsi ginjal dan hati yang normal dimasukkan ke dalam kajian. Sejumlah 
22 pasien memenuhi kriteria dengan jumlah siklus kemoterapi sebanyak 40. Hasil kajian ini mengungkap 
bahwa kombinasi karboplatin-paklitaksel merupakan kemoterapi yang paling banyak digunakan 
(72,2%). Toksisitas hematologis yang terjadi meliputi anemia, leukopenia, dan trombositopenia dengan 
tingkat keparahan 1–3. Karboplatin-paklitaksel merupakan satu-satunya kombinasi kemoterapi yang 
menyebabkan ketiga toksisitas hematologis tersebut, sekaligus juga merupakan satu-satunya kombinasi 
yang menimbulkan trombositopenia. Anemia merupakan toksisitas hematologis yang paling banyak 
terjadi meliputi lebih dari separuh pasien. Penelitian ini menyimpulkan bahwa terdapat toksisitas hematologis 
yang cukup tinggi akibat kemoterapi pada pasien kanker paru. 
Kata kunci: Anemia, kanker paru, kemoterapi, leukopenia, toksisitas hematologis, trombositopenia
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Introduction
Lung cancer is a disease of uncontrolled growth 
of cells that starts off in one or both lungs. Most 
of the lung cancers such as lung carcinomas are 
derived from epithelial cells.1 Lung cancer is 
ranked fourth of all cancers in Indonesia and 
has become the second leading cause of death 
after cardiovascular disease.2,3 Lung cancer 
management is conducted with a series of 
treatment such as surgery, radiation therapy, 
chemotherapy, and combination therapy.4 Some 
chemotherapeutic agents such as cisplatin and 
carboplatin are well-known for their poor 
therapeutic index and with high toxic effects, 
thus improper doses and regimens may result 
in some serious adverse effects and fatalities. 
Chemotherapy drugs generally work on cells 
that are actively dividing. Therefore, the effect 
is not only experienced by the cancerous cells 
but also in normal tissues with a high rate 
of proliferation such as gastrointestinal and 
hematopoietic systems.5
First-line regimens of chemotherapy that are 
recommended by The National Comprehensive 
Cancer Network (NCCN) for Lung Cancer 
comprise a combination of platinum (cisplatin or 
carboplatin) with other cytotoxic drugs, such as 
paclitaxel, gemcitabine, vinorelbine, pemetrexed, 
and docetaxel.6 Cisplatin and carboplatin are 
nephrotoxic cytotoxic agents that can contribute 
to a decrease in creatinine clearance up to 60–
80%. On the other hand, carboplatin is reported 
to have smaller nephrotoxicity. However, the 
accumulation of its long-term use may also cause 
similar toxic effects. Renal tubular damage 
induced by cisplatin or carboplatin may affect 
the pharmacokinetics of cisplatin which is 
excreted by the kidney. The concentration of 
unbound molecules of these two drugs may 
increase, causing a reduced renal excretion 
after several cycles. As a consequence, their 
myelosuppressive effect on bone marrow 
activity can be worsening.7
The clinical manifestation of myelo- 
suppressive effect may present as anemia, 
leukopenia, and thrombocytopenia. Severe 
leukopenia (leukocyte count <2000/mm3) and 
thrombocytopenia (platelet count <100,000/
mm3) are adequate indicators to discontinue 
therapy in patients whose hematopoietic system 
were normal at the beginning of therapy.5,8 
The grade of toxicity has also become one 
of the criteria to take into account before 
conducting chemotherapy. Chemotherapy can 
only be prescribed when the toxicity does not 
exceed grade three based on the WHO toxicity 
grading scale. Therefore, it is necessary to 
study the toxicity of chemotherapy for lung 
cancer patients and to monitor the toxicity 
scale.9
Methods
Study design
The study was a qualitative descriptive research 
conducted by the cross-sectional method using 
four-year medical record data of male and 
female lung cancer patients in 2010–2014 who 
underwent chemotherapy at the pulmonary 
ward in Dr. M. Djamil Hospital, Padang, West 
Sumatra, Indonesia. Samples were collected 
using total sampling technique. This study has 
been approved by the hospital’s Education and 
Research Office (No. LB.00.02.07.1971). 
Population and sample
The population was all medical records of 
patients who had been diagnosed with lung 
cancer and underwent chemotherapy at the 
pulmonary ward of Dr. M. Djamil Hospital 
Padang, West Sumatra, Indonesia. Data were 
collected from patients’ medical records that met 
inclusion criteria: diagnosed with lung cancer 
and received first-line chemotherapy regimens. 
Patients who underwent chemoradiotherapy 
and those diagnosed with primary hematologic 
diseases or impaired kidney and liver function 
before chemotherapy were excluded from the 
study.
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Data collection and analysis
The collected data consisted of types and stages 
of lung cancer, regimens of chemotherapy, 
performance status, and the results of the 
hematologic examination. Staging of cancer 
was based on TNM classification system 
converted into stage I to IV,10,11 meanwhile 
the grading for hematological toxicities was 
based on WHO toxicity scale taken from 
hemoglobin levels, leukocyte, granulocytes 
and platelet counts.12 The performance status 
of the patients was examined using the 
Karnofsky scale to assess their capability to 
tolerate the use of chemotherapeutics.13 Data 
were analyzed descriptively and presented in 
tables and charts. 
Results
Among 46 lung cancer patients who received 
chemotherapy, a number of 22 patients met the 
criteria for the study with a total of 40 cycles of 
chemotherapy. The patients were dominated 
by male (68.2%) and those aged 41–60 years 
old (72.8%). Adenocarcinoma was the most 
common type of lung cancer found in the 
study (77.3%). The characteristics of lung 
cancer patients receiving chemotherapy are 
presented in Table 1, meanwhile, the number 
of chemotherapy cycles received by the patients 
is demonstrated in Figure 1, in which most of 
the patients (68.2%) received only one cycle 
of chemotherapy.
Table 1 Characteristics of Lung Cancer Patients Receiving Chemotherapeutic Agents
Patient Characteristics Number of Patients Total (%)
Sex
  Male 15 68.2
  Female   7 31.8
Age 
  21–30   1    4.5
  31–40   2    9.1
  41–50   8 36.4
  51–60   8 36.4
  61–70   1    4.5
  71–80   2    9.1
Type of Lung Cancer
  Adenocarcinoma 17 77.3
  Squamous cell carcinoma   3 13.6
  Large cell carcinoma   2    9.1
Staging*
  IIB   3 13.6
  IIIA   2    9.1
  IIIB   1    4.5
  IV 16 72.7
Performance Status**
  30–40%   0    0.0
  50–60%   0    0.0
  70–80% 22 55.0
  90–100% 18 45.0
*Based on TNM classification (T for extent of the primary tumor, N for involvement of lymph nodes, and M for distant 
metastases)14,15, **Based on Karnofsky Performance Status Scale13
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There was a total of four combinations of 
chemotherapeutic agents used by the patients. 
Carboplatin-paclitaxel was the most frequent 
combination in all three types of lung cancer 
(72.2%). Table 2 summarizes entire combinations 
of chemotherapeutic agents used by the 
patients in different types of lung cancer. 
On the other hand, there were three different 
hematologic toxicities (dominated by anemia) 
investigated from the patients caused by three 
out of four chemotherapeutic combinations. 
Thrombocytopenia was experienced by all 
patients who received carboplatin -paclitaxel 
(Table 3). The number of chemotherapy cycles 
causing hematologic toxicities and their grading 
distribution is presented in Figure 2.
Discussion
Surgery and radiation therapy are powerful 
treatments to remove and destroy cancer cells. 
However, this kind of treatment can only work 
in certain body areas. Chemotherapeutic agents 
come to solve this limitation because they can 
work throughout the whole body and even kill 
cancerous cells that have metastasized to other 
body parts.5 Unfortunately, chemotherapy poses 
a major concern in adverse effects to some 
organ systems, including hematologic functions. 
Some of them are considered to cause fatalities 
and death, especially in elderly patients.14,15 In 
addition, the evaluation of hematologic toxicities 
from chemotherapy, especially for lung cancer 
patients in Indonesia, is rare to be reported to 
our knowledge. Therefore, the evaluation of 
hematologic toxicities is a necessary initial step 
towards improving the quality of the treatment 
and the patients’ quality of life as well.
In the present study, the combinations of 
chemotherapeutic agents were investigated for 
their toxic effects to the hematologic system, 
especially for the three major components of 
Table 2 Combinations of Chemotherapeutic Agents Used in Several Types of Lung Cancer
Chemotherapeutic 
Combination
Number of Patients (%)
Adenocarcinoma Squamous Cell Carcinoma
Large Cell 
Carcinoma Total
Carboplatin-Paclitaxel 12 (72.7) 1 (50.0) 3 (100.0) 16 (72.7)
Carboplatin-Gemcitabine   2 (11.8) 1 (50.0) -   3 (13.6)
Carboplatin-Vinorelbine   2 (11.8) - -     2 (9.1)
Cisplatin-Gemcitabine     1 (4.4) - -     1 (4.4)
Figure 1 Percentage of Patients Who Received Certain Cycles of Chemotherapy for Lung Cancer (n=22)
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blood cells. The grade for these toxic effects 
was based on the Karnofsky performance scale, 
a very popular scaling system to determine the 
patients’ capability to tolerate the medications 
that they receive, especially for serious illness 
such as the use of chemotherapy for cancer 
patients. The Karnofsky score is presented 
in percent, in which the lower the score, the 
worse the rate of survival. Simply put, 100 
means perfect health while 0 means death.13 On 
the other hand, the staging of the lung cancer 
suffered by the patients was determined by 
TNM classification. This classification system 
is based on the anatomical extent of the cancers 
that represents the size of the tumour (T), the 
involvement of the lymph node (N), and the 
metastasis status (M).10,11 The study found 
that the toxic effects were present in most of 
the chemotherapeutic combinations. These 
toxicities comprised anemia, leukopenia, 
and thrombocytopenia with various severity 
ranging from grade 1 to 3. 
The data show a marked difference between 
the number of male and female patients. A 
report from the US Centers for Disease Control 
and Prevention (CDC) suggests that men are 
more likely to be suffering from lung cancer 
than women.16 The American Cancer Society 
also approximates that the overall risk of 
developing lung cancer in men is around 1 in 
14, higher when compared to a 1 in 17 chance 
for women. In addition, the risk becomes 
higher when the individual smokes tobacco.17 
Although not assessed in the present study, 
evidence suggests that tobacco smoking 
is the major cause of lung cancer. In fact, 
Indonesia has been reported to have 76.2% 
more men smokers than on average countries 
with medium human development index. In 
contrast, tobacco smoking among women 
Table 3 The Incidence of Hematologic Toxicities in Patients Receiving Combination of Chemotherapeutic 
              Agents for Lung Cancer
Chemotherapeutic 
Combination
Number of 
Patients (%)
Number of Incidence of Toxicity (%)
Anemia Leukopenia Thrombocytopenia
Carboplatin-Paclitaxel 16 (72.7) 8 (50.0) 5 (31.3) 16 (100.0)
Carboplatin-Gemcitabine   3 (13.6) 2 (66.7) - -
Carboplatin-Vinorelbine    2 (9.1) 1 (50.0) 1 (50.0) -
Cisplatin-Gemcitabine    1 (4.5) - - -
Figure 2 Number of Chemotherapy Cycles with Hematological Toxicities and Their Grading Distribution (n=40)
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is 3.6% fewer.18 However, although more 
smoking men were presented than women, 
studies show more significant percentage of 
women who develop lung cancer have never 
smoked.19,20 Another risk factor that could 
differentiate between sexes is the biological 
aspects. These include the genes that may make 
them more vulnerable to harmful effects of 
carcinogens.21 The various genetic association 
is also proposed to either increase the risk 
of developing the disease or preventing it.22 
Besides, the difference in hormonal regulation 
may influence the progression of cancer 
between men and women.23
The present findings show that most of 
the patients had adenocarcinoma (77.3%), in 
line with the global trend in most parts of the 
world.24,25 Higher incidence of adenocarcinoma 
is often correlated with its risk factor. Some 
studies have suggested that the shift in the use of 
cigarette filter ventilation might be responsible 
for the increasing number of this type of lung 
cancer.26,27 Another striking data from the 
present study was the highest percentage of 
patients with stage IV lung cancer (72.7%). 
Ellis and Vandermeer (2011) have found that 
lung cancer patients, in general, experience 
considerable delays from the progression of 
the cancer symptoms to present to the medical 
provider for examination and then to initiate 
the appropriate treatment. This delay may 
result in the advancing of the cancer stage.28 
Nevertheless, the performance status of all 
patients are noticeably good (at least 70%). 
The score 70% represents the patients’ inability 
to carry on normal activities but still care for 
self. Meanwhile, the patients with 80% score 
can be active for work with efforts although 
some signs or symptoms of the disease are 
experienced. On the other hand, patients 
scored 90% can carry on normal activity with 
minor signs or symptoms of the disease.13
A previous study has demonstrated that 
the toxicity of chemotherapy depends on the 
doses received by the patients.5 However, the 
present study found that the doses of drugs 
used in chemotherapy were all appropriate in 
accordance to the recommendation of NCCN 
and The Indonesian Society of Respirology, 
where the doses should be calculated based 
on patient’s body surface area especially for 
paclitaxel, gemcitabine, vinorelbine, and based 
on the kidney function for carboplatin.6,9 Hence, 
the use of chemotherapy beyond recommended 
doses might not be considered as the causing 
factor for toxicities of chemotherapy in the 
present study.
Many severe toxicities in the use of 
chemotherapeutic agents are often experienced 
during the first cycle of chemotherapy. 
Hematologic toxicities from chemotherapy 
may generally occur from the first to eighteenth 
week and most commonly arise in the fifth 
week or at the end of the second cycle.29,30 The 
present study found that hematologic toxicities 
progressed at the end of the second cycle of 
chemotherapy, where the grade 3 toxicity 
increased dramatically from 0 to 37.50%. 
This might occur because the chemotherapy 
drugs, in addition to destroying the cancer 
cells, also kill progenitor cells that produce 
granulocytes, erythrocytes, and platelets in 
peripheral blood circulation. These immature 
cells will be destroyed within 7–14 days after 
chemotherapy, while the maturation of those 
cells in the bone marrow takes 8–12 days, 
therefore those blood components will return 
to normal level on day 28–35.30
Anemia is the most common hematologic 
toxicity found in this study (30%). Fortunately, 
its highest incidence (50%) was the grade 1 
anemia. The proper dose of chemotherapy 
might contribute to prevent the incidence of 
high-grade toxicity of anemia, and perhaps 
also for leukopenia and thrombocytopenia as 
it is well recognized that higher doses would 
bring about greater hematologic toxicities.30 
The present data also showed that most of 
the patients (68.2%) only received 1 cycle of 
chemotherapy (Figure 1). The chemotherapy 
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cycle is reported to be associated with the 
severity of the toxicity. The more the number 
of chemotherapy cycles, the more severe the 
toxicity experienced by the patients.31 
A number of 11 patients experienced 
anemia in this study: 8 from those who 
used carboplatin-paclitaxel (50%); 2 from 
carboplatin-gemcitabine (67%); and 1 from 
carboplatin-vinorelbine (50%) as shown in 
Table 3. Patients who experienced anemia in 
this study were those using a combination of 
carboplatin with another anticancer agent. The 
percentage of anemia toxicity among patients 
who received a combination of carboplatin 
with paclitaxel; gemcitabine; and vinorelbine 
were 50; 66.67, and 50%, respectively. A 
previous study has also found that most common 
hematologic toxicity from a combination of 
platinum-gemcitabine was anemia.32 
Generally, a combination of platinum-
gemcitabine has been well recognized as 
the third generation of chemotherapy agent 
which often causes both hematologic and non-
hematologic toxicities.32-35 Gemcitabine is a 
prodrug that is metabolized and activated in 
the liver, while the clearance of this drug from 
the body is undertaken through the kidneys. 
Clearly, both liver and kidney play significant 
roles in the pharmacokinetics of this drug.36 
Therefore, the use of this combination is not 
only leading to decreased kidney function 
through the mechanism of hypomagnesemia 
due to carboplatin, but also angiopathy lesions 
in the nephrons due to gemcitabine. In addition, 
kidney and liver also play particular roles in the 
secretion of erythropoietin which is important in 
the production of blood cells, thus alteration 
to these organs is very likely to contribute to 
anemia.37 
Besides causing anemia, chemotherapy 
can also cause leukopenia, a decrease in the 
number of white blood cells. Herein, this kind 
of hematologic toxicity was found in 15% 
of the patients, all of them were within grade 
1–2. This grade of toxicity is considered to 
not interfere with the chemotherapy. Several 
factors reported to significantly affect the 
incidence of leukopenia in chemotherapy 
with platinum-based regimens include age, 
sex, creatinine clearance, and BMI.38 
All patients who experienced leukopenia 
from chemotherapy were male subjects, aged 
<65 years old. Nevertheless, both sex and 
age factors are difficult to be correlated with 
the incidence of leukopenia in this study. The 
incidence of leukopenia was experienced by 
6 patients, where 5 of them were those taking 
carboplatin-paclitaxel (31% among this group) 
and the rest (1 patient) taking carboplatin-
vinorelbine combination (55%). Some previous 
studies reported higher incidence (45% and 
72%) of leukopenia among patients taking a 
combination of platinum with paclitaxel,39,40 
while number of patients taking carboplatin-
vinorelbine who experienced leukopenia from 
other studies has been reported to vary from 
21% to 70%.41,42
It can be shown from the present data 
that thrombocytopenia was experienced in 
5% of the total cycles, where all of them 
were in grade 3 toxicity. Thrombocytopenia 
occurred at the end of cycle 2 and 4. These 
patients were those who took carboplatin-
paclitaxel combination. Previous studies have 
also reported that around 10–11% of patients 
who took carboplatin-paclitaxel combination 
experienced grade 3–4 thrombocytopenia. 
However, thrombocytopenia is a quite rare 
hematologic toxicity from the use of platinum 
and paclitaxel combination.30,43 
A major limitation of the present study 
is the limited number of patients although 
lung cancer is reported to be the number 
one cancer that kills men and the leading 
cause of economic burden in Indonesia.44 
The use of four-year data in this study could 
not even increase a significant number of 
data for inclusion, thus did not allow some 
more sophisticated statistical analyses to 
be conducted. Nonetheless, the number of 
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samples in this study was quite representative 
since the total sampling technique was used, 
thus reducing the risk of missing potential 
insights from samples that were not included. 
In addition, incomplete and insufficient 
details within the medical records are other 
issues in collecting more data from a wider 
period. Future studies may need to consider 
collecting and evaluating the data from 
multiple hospitals. More data will allow further 
analysis that may involve comparative and 
correlative analyses from the patients’ socio-
demographic profile. On the other hand, the 
use of electronic medical records should be 
implemented to improve the transition to the 
digital age. This implementation is not only 
supporting the research but also improving 
the quality of service and coordination of the 
healthcare providers.45,46 
The incidence of hematologic toxicities 
from chemotherapy may be avoided by 
studying the patients’ individual risk factors. 
Several predictors have been proposed beyond 
the average risks. A scoring system known 
as The Chemotherapy Risk Assessment 
Scale for High-Age Patients (CRASH) for 
example, has been proposed to assess the 
risk of chemotherapy in elderly patients.47 
On the other hand, clinical pharmacists may 
take a critical role in improving the safety 
of chemotherapy by identifying the type of 
chemotherapy errors, their frequency, and their 
severity, in addition, to provide supportive 
care such as managing nausea and vomiting 
symptoms and hematologic issues experienced 
due to chemotherapy. Pharmacists are also 
encouraged to participate in nutrition and 
control of infection.48 These responsibilities 
should be promoted to improve healthcare 
quality and patient safety, especially in the use 
of chemotherapeutic agents.
Conclusions
The incidence of hematologic toxicities of 
chemotherapy in lung cancer patients who 
received the platinum anticancer drugs at 
Dr. M. Djamil Hospital Padang, Indonesia 
comprised anemia (30%), leukopenia (15%) 
and thrombocytopenia (5%). These toxicities 
were ranging from grade 1 to 3. Further research 
needs to be conducted analytically related to 
risk factors for hematologic toxicities among 
these patients, thus the management can be 
delivered more effectively and safer.
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